190 related articles for article (PubMed ID: 9593049)
1. An overview of progress in antisense therapeutics.
Crooke ST
Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):115-22. PubMed ID: 9593049
[No Abstract] [Full Text] [Related]
2. Antisense therapeutics.
Agrawal S; Zhao Q
Curr Opin Chem Biol; 1998 Aug; 2(4):519-28. PubMed ID: 9736926
[TBL] [Abstract][Full Text] [Related]
3. A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides.
Levin AA
Biochim Biophys Acta; 1999 Dec; 1489(1):69-84. PubMed ID: 10806998
[No Abstract] [Full Text] [Related]
4. Pharmacology of therapeutic oligonucleotides.
Diasio RB; Zhang R
Antisense Nucleic Acid Drug Dev; 1997 Jun; 7(3):239-43. PubMed ID: 9212918
[No Abstract] [Full Text] [Related]
5. Synthetic oligonucleotides: the development of antisense therapeutics.
Monteith DK; Levin AA
Toxicol Pathol; 1999; 27(1):8-13. PubMed ID: 10367666
[TBL] [Abstract][Full Text] [Related]
6. Nucleic acid therapeutics: state of the art and future prospects.
Gewirtz AM; Sokol DL; Ratajczak MZ
Blood; 1998 Aug; 92(3):712-36. PubMed ID: 9680338
[No Abstract] [Full Text] [Related]
7. Review of in vivo pharmacokinetics and toxicology of phosphorothioate oligonucleotides.
Srinivasan SK; Iversen P
J Clin Lab Anal; 1995; 9(2):129-37. PubMed ID: 7714665
[No Abstract] [Full Text] [Related]
8. Design and application of antisense oligonucleotides in cell culture, in vivo, and as therapeutic agents.
Brysch W; Schlingensiepen KH
Cell Mol Neurobiol; 1994 Oct; 14(5):557-68. PubMed ID: 7621513
[TBL] [Abstract][Full Text] [Related]
9. Genetic therapy for transplant vascular sclerosis.
Bennett CF; Stepkowski SM
Transpl Immunol; 1997 Dec; 5(4):299-302. PubMed ID: 9504151
[No Abstract] [Full Text] [Related]
10. Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man.
Iversen PL; Copple BL; Tewary HK
Toxicol Lett; 1995 Dec; 82-83():425-30. PubMed ID: 8597088
[TBL] [Abstract][Full Text] [Related]
11. Progress in antisense oligonucleotide therapeutics.
Crooke ST; Bennett CF
Annu Rev Pharmacol Toxicol; 1996; 36():107-29. PubMed ID: 8725384
[TBL] [Abstract][Full Text] [Related]
12. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides.
Geary RS; Leeds JM; Henry SP; Monteith DK; Levin AA
Anticancer Drug Des; 1997 Jul; 12(5):383-93. PubMed ID: 9236854
[No Abstract] [Full Text] [Related]
13. Toward antisense oligonucleotide therapy for cancer: ISIS compounds in clinical development.
Holmlund JT; Monia BP; Kwoh TJ; Dorr FA
Curr Opin Mol Ther; 1999 Jun; 1(3):372-85. PubMed ID: 11713802
[TBL] [Abstract][Full Text] [Related]
14. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
15. Brief overview of control of genetic expression by antisense oligonucleotides and in vivo applications. Prospects for neurobiology.
Zon G
Mol Neurobiol; 1995; 10(2-3):219-29. PubMed ID: 7576309
[TBL] [Abstract][Full Text] [Related]
16. Toxicological and pharmacokinetic properties of chemically modified antisense oligonucleotide inhibitors of PKC-alpha and C-raf kinase.
Henry SP; Monteith D; Bennett F; Levin AA
Anticancer Drug Des; 1997 Jul; 12(5):409-20. PubMed ID: 9236856
[No Abstract] [Full Text] [Related]
17. Application of antisense technology to therapeutics.
Heidenreich O; Kang SH; Xu X; Nerenberg M
Mol Med Today; 1995 Jun; 1(3):128-33. PubMed ID: 9415148
[TBL] [Abstract][Full Text] [Related]
18. Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication.
Henry SP; Miner RC; Drew WL; Fitchett J; York-Defalco C; Rapp LM; Levin AA
Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2646-51. PubMed ID: 11581212
[TBL] [Abstract][Full Text] [Related]
19. Antisense strategies for oncogene inactivation.
Stein CA; Benimetskaya L; Mani S
Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
[TBL] [Abstract][Full Text] [Related]
20. Antisense oligonucleotides in cutaneous therapy.
Wraight CJ; White PJ
Pharmacol Ther; 2001 Apr; 90(1):89-104. PubMed ID: 11448727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
